BioNTech (NASDAQ:BNTX) Given New $94.00 Price Target at TD Cowen

BioNTech (NASDAQ:BNTX) had its target price decreased by TD Cowen from $116.00 to $94.00 in a research report report published on Wednesday morning,Benzinga reports. TD Cowen currently has a hold rating on the stock.

A number of other equities analysts have also recently issued reports on BNTX. Morgan Stanley decreased their price objective on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday. Bank of America reissued a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $140.00 price target on shares of BioNTech in a report on Thursday, December 11th. UBS Group upgraded BioNTech to a “hold” rating in a report on Thursday, December 4th. Finally, Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research report on Tuesday. Twelve analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Trading Up 8.3%

NASDAQ:BNTX opened at $90.84 on Wednesday. The firm has a market capitalization of $20.46 billion, a P/E ratio of -17.34 and a beta of 1.51. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $106.64 and a 200 day moving average of $102.75. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after acquiring an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new position in shares of BioNTech in the 1st quarter valued at approximately $167,000. Envestnet Asset Management Inc. boosted its position in shares of BioNTech by 20.6% during the second quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock valued at $1,125,000 after purchasing an additional 1,808 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in BioNTech in the second quarter worth $303,000. Finally, Profund Advisors LLC grew its stake in BioNTech by 3.6% in the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after purchasing an additional 149 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS -$0.39 vs -$0.57 expected; revenue ~$1.06B vs $942M expected); management highlighted a strong cash position and multiple upcoming late‑stage readouts. Earnings Press Release
• Positive Sentiment: Analysts remain generally constructive: Canaccord reaffirmed a Buy with a $171 PT and Goldman Sachs also reaffirmed Buy — these positive analyst stances can support near‑term buying interest. Canaccord Note
• Neutral Sentiment: BioNTech announced plans to contribute certain rights/technologies to a new independent company led by co‑founders; BioNTech will retain a minority stake and may receive milestones/royalties — could free focus/resources but adds execution complexity. Company Release
• Neutral Sentiment: Reported short‑interest data in March shows zero shares (likely a reporting/data anomaly) — not meaningful for sentiment at this time.
• Negative Sentiment: Co‑founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to leave by end of 2026 to launch a new mRNA company — markets view founder exits as a governance and execution risk, which triggered heavy selling. Reuters
• Negative Sentiment: FY‑2026 revenue guidance was lowered materially (company now sees ~€2.0–2.3B vs consensus nearer €3.1B) — the weaker outlook is a primary driver of the recent selloff. Full Results & Guidance
• Negative Sentiment: Multiple outlets reported a steep one‑day stock drop after the earnings/guidance and founder news; several brokers have cut price targets (Jefferies, Citigroup, BMO lowered PTs; TD Cowen moved to Hold) — analyst downgrades/PT cuts amplify downside pressure. Analyst Notes Summary
• Negative Sentiment: Investor litigation/claims firm Johnson Fistel announced an inquiry into potential shareholder claims related to executive actions — adds legal/ reputational overhang. Johnson Fistel Notice

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.